secwatch.observer — SEC 8-K summary
======================================

Issuer:     Turn Therapeutics Inc. (TTRX)
CIK:        0002023016
Form:       8-K
Filed at:   2026-05-18T12:15:16+00:00
Accession:  0001213900-26-058140
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Turn Therapeutics appoints former FDA Commissioner Dr. Stephen Hahn as clinical and regulatory lead
--------------------------------------------------------------------------------

- Dr. Stephen M. Hahn, former FDA Commissioner, appointed to oversee clinical and regulatory strategy for GX-03.
- GX-03 is a topical therapy in Phase 2 trial for moderate-to-severe atopic dermatitis (eczema).
- Hahn cited personal family experience with atopic dermatitis as motivation for his role.
- CEO Bradley Burnam highlighted Hahn's scientific rigor, regulatory expertise, and patient focus.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026058140/0001213900-26-058140-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026058140/ea0291223-8k_turn.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-058140

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer